Biopeople

Science and finance expert

Science and finance expert

12.07.2014 - Will Lewis has joined Uniqure’s supervisory board in June 2014. The human gene therapy specialist company expects to profit from Lewis’ expertise in both scientific and financial aspects of management as well as experience in orphan diseases.

Will Lewis has more than 20 years of executive experience in the pharmaceutical and finance industries both in the US and internationally. He served as president and CEO and as a member of the Board of Directors of Insmed, a US biopharma company specialised in inhalation therapies for orphan lung diseases. He co-founded Aegerion Pharmaceuticals, where he also filled the role of president and chief financiel officer. Prior to Aegerion, Lewis spent 10 years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo.

Lewis also serves as a member of the board of directors of Oberlin College and is a member of the Visiting Committees of the Weatherhead School of Management of Case Western Reserve University and The Hawken School. Jörn Aldag, CEO of uniQure, commented “[Lewis’] exceptional experience in the field of orphan diseases as well as his broad knowledge of the US and European financial markets will be of high value to the company.”

25.03.2014 British late-stage drug co-developer Avillion LLP appointed Dr. Allison Jeynes-Ellis to the post of Chief Executive Officer in February.

Dianna Bonner

The company’s cofounder and former CMO previously worked in senior roles at various pharmaceutical companies, including Wyeth, Bristol-Myers Squibb and Novartis. She has also acted as an independent consultant to many companies – including CAT and Genentech – as well as government bodies and medical research charities.

20.03.2014 In-vitro diagnostics instrumentation and software specialist Stratec Bio-medical AG (Birkenfeld) has appointed Claus Vielsack to its management board as Product Development Director.

Stratec Biomedical

Vielsack (46) has held various senior product development positions at Stratec since 1998. Before joining the Dx specialist, he held a number of different positions working as a programme manager in the development of chemical applications and software solutions.

18.03.2014 The European Medicines Agency (London) has named Dina Tsiambaou to head its IT Development Department.

EMA

She joins the Agency from Accenture, where she has had a long career defining, leading and delivering complex IT transformation and implementation projects. As with all EMA staff members, Tsiambaou will have to declare her interests in the pharmaceutical industry and divest herself of any shares she might own in pharmaceutical companies before beginning work at the Agency.

14.03.2014 Sartorius AG (Göttingen) has tapped the former CEO of analytical instruments provider Methrom’s US division to head marketing, sales and services at the firm’s Lab Products & Services Division.

Sartorius AG

Michael Melingo succeeds Dominique Baly, who is retiring. The new member of the Executive Committee – the highest operational management level in the Sartorius Group – brings in more than 30 years of experience in the industry. Prior to Methrom, the bioengineer worked as a sales and marketing executive with Baxter, Bio-Rad, Millipore and Waters in Europe and Asia.

12.03.2014 Medical device developer Vexxim SA (Toulouse) has named Sandrine Carle (43) to the post of Marketing Director.

Vexxim

Carle, who came in from Medtronics, will be responsible for the expansion of Vexxim’s business in new international markets. After graduating with a Master’s in Biomedical Engineering from Compiègne University of Technology (France) in 1994, she began her industry carreer at Aescula. In 2013, she obtained an Executive MBA from HEC Paris.

06.03.2014 Kemal Malik (51) has been appointed to the Board of Bayer AG.

Bayer AG

Malik has been a member of the Bayer HealthCare Executive Committee and its Head of Global Development and Chief Medical Officer since 2007. He is to succeed Prof. Wolfgang Plischke, who is retiring. In his new position, Malik will be responsible for innovation, and is taking over responsibility for the North America region. Before joining Bayer in 1995, the physician held various positions of increasing responsibility at Bristol-Myers Squibb. At Bayer, he served as Head of Global Medical Development before being appointed Head of Global Development.

03.03.2014 Robert Cascella has joined Edinburgh-based DySIS Medical as Chairman of its board.

DySIS Medical

He joins the medical devices company from diagnostics firm Hologic Inc. where Cascella was Chief Executive Officer. Prior to Hologic, the expert from the women’s healthcare industry served as a Managing Partner of the investment banking firm CFG Capital LLC, and also had a stint as the Chief Operating Officer and Vice President of Finance at NeoVision Corporation.

28.02.2014 Enzyme manufacturer Royal DSM and Roquette Frères joint-venture Reverdia named a new president at the beginning of 2014.

Marcel Lubben, who steps in for former General Manager Will van den Tweel, will be responsible for pushing growth in the emerging market for sustainably produced bio-based succinic acid. The new appointee certainly appears to have the commercial and business leadership experience required for that challenge. Lubben held positions in Research, Business Development and Marketing & Sales in DSM Pharma Chemicals and DSM Biologics before transitioning into the industrial biotech­nology sector. In 2009, he was appointed Managing Director Licensing for DSM, and became Managing Director Venturing & Licensing in 2011. In 2012 he became Vice President Bio-based Chemicals & Materials. The new President also served as a member of the Reverdia board from mid-2012 until the end of 2013.

27.02.2014 Ramin Ronny Amirsehhi, founder of Amirsehhi Intellectual Property Law, has moved his office from San Francisco to the innovation and start-up center for biotechnology (IZB) in Martinsried.

Amirsehhi has more than ten years of patent prosecution experience. Prior to founding Amirsehhi Intellectual Property Law three years ago, he worked at Kenyon & Kenyon LLP in New York and Bird & Bird in Munich. In addition, he has served as in-house intellectual property counsel to Epigenomics AG in Berlin. Amirsehhi is earning his PhD in intellectual propetry law, his certificates in Pharmacogenomics and Nanobiotechnology. He received his master degree in Intellectual Property Law from Munich Intellectual Property Law Center partnering with the Max Planck Institute for Intellectual Property, Competition and Tax Law, the University of Augsburg, the Technische Universität München, and the George Washington University Law School in Washington, D.C. (USA). He studied Bioengineering with focus on biochemistry, organic chemistry, and molecular biology at University of California-San Diego. Armirsehhi represents clients in examination and opposition proceedings before the European Patent Office and the United States Patent and Trademark Office. His technical focus is in the field of biotechnology, biosimilars, nanomedicine, and pharmaceutical chemistry.

25.02.2014 The European biotechnology industry association EuropaBio has named Beat Spaeth as its new Director of Agricultural Biotechnology.

He is assuming the post in mid-February. The German and Swiss national has been working for the association as its Public Affairs Manager and Senior Manager in the agri-biotech team since 2011, and has many years of experience in European public affairs. Spaeth is taking over from Carel du Marchie Sarvaas, who has led EuropeBio’s agricultural biotech team for the past four years.

Vorherige Seite3/19Nächste Seite

Events

All Events

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR303.8%
  • SANTHERA (CH)68.90 CHF102.6%
  • ADDEX (CH)4.06 CHF82.1%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-29.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)68.90 CHF3433.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP769.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)9.69 EUR-69.2%

No liability assumed, Date: 23.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products